Maryland Technology Development Corporation - Maryland Advanced Manufacturing Grant Program - Established
Summary
SB905 establishes the Maryland Advanced Manufacturing Grant Program within the Maryland Technology Development Corporation (TEDCO). The program is intended to support the growth of companies specializing in regenerative medicine and other advanced manufacturing by offering grants for eligible projects. TEDCO, in consultation with the Maryland Stem Cell Research Commission, must set eligibility standards, application and evaluation procedures, and grant award processes and amounts.
Grant funds may be used only for acquiring, renovating, or constructing space for regenerative medicine or other advanced manufacturing, making necessary infrastructure improvements, and purchasing needed equipment. The bill also creates a special, nonlapsing Maryland Advanced Manufacturing Grant Program Fund to finance grants and administrative costs, with money coming from state appropriations, interest earnings, and other accepted sources. The fund is administered by TEDCO and is exempted from the general rule that certain interest earnings on state money revert to the General Fund.
Impact
The bill adds a new section to the Economic Development Article establishing a new state grant program and fund, and it amends the State Finance and Procurement Article to exempt the new fund from the interest-earnings transfer rule that would otherwise send net interest to the General Fund. It gives TEDCO new administrative responsibilities and authorizes consultation with the Maryland Stem Cell Research Commission on regenerative medicine-related criteria and regulations. The practical effect is to create a dedicated state financing mechanism for advanced manufacturing and regenerative medicine projects, potentially benefiting companies seeking capital for facilities, infrastructure, and equipment.
Sentiment
The available voting history suggests broad legislative support for the bill. It passed the Senate unanimously and later passed the House with a strong majority, indicating that lawmakers generally viewed the program favorably as an economic development and innovation initiative. No committee transcript excerpts were provided, so there is no recorded debate in the supplied materials showing organized opposition or significant reservations.
Contention
The main policy choice in the bill is the use of state resources to support a targeted industry through grants and a dedicated fund, rather than leaving such investments to the private market. Any contention would likely center on whether the state should subsidize regenerative medicine and advanced manufacturing, how grant recipients are selected, and whether the fund should be exempt from returning interest earnings to the General Fund. The bill text itself does not show explicit opposition, and the recorded votes suggest little controversy in the final legislative process.